Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
Clinical Pharmacology in Drug Development
|
June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants
Hwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Open Forum Infectious Diseases
|
November 26, 2020
In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant <i>Pseudomonas Aeruginosa</i>
Donna Carr, Zufei Zhang, Qian Si, et al.
European Journal of Clinical Pharmacology
|
February 25, 2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel
William L Marshall, Hwa-Ping Feng, Luzelena Caro, et al.
Critical Care (London, England)
|
October 3, 2021
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
Andrew F Shorr, Christopher J Bruno, Zufei Zhang, et al.
Antimicrobial Agents and Chemotherapy
|
September 13, 2021
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
Dan Li, Philip E Sabato, Benjamin Guiastrennec, et al.
Clinical Drug Investigation
|
February 2, 2021
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults
Luzelena Caro, Thomayant Prueksaritanont, Christine M Fandozzi, et al.
Clinical Pharmacology : Advances and Applications
|
February 28, 2020
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
Haiyan Li, Zhenhua Yang, Shuang Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2012
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir
Ellen G J Hulskotte, Hwa-Ping Feng, Fengjuan Xuan, et al.
Clinical Therapeutics
|
May 5, 2018
A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants
Tommy Tsang Cheung, Joanne Wing Yan Chiu, Man Fung Yuen, et al.
Clinical Therapeutics
|
August 30, 2018
Corrigendum to "A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants" [Clinical Therapeutics 40 (2018) 719-732]
Tommy Tsang Cheung, Joanne Wing Yan Chiu, Man Fung Yuen, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
Clinical Pharmacology in Drug Development
|
June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants
Hwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Open Forum Infectious Diseases
|
November 26, 2020
In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant <i>Pseudomonas Aeruginosa</i>
Donna Carr, Zufei Zhang, Qian Si, et al.
European Journal of Clinical Pharmacology
|
February 25, 2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel
William L Marshall, Hwa-Ping Feng, Luzelena Caro, et al.
Critical Care (London, England)
|
October 3, 2021
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
Andrew F Shorr, Christopher J Bruno, Zufei Zhang, et al.
Antimicrobial Agents and Chemotherapy
|
September 13, 2021
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
Dan Li, Philip E Sabato, Benjamin Guiastrennec, et al.
Clinical Drug Investigation
|
February 2, 2021
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults
Luzelena Caro, Thomayant Prueksaritanont, Christine M Fandozzi, et al.
Clinical Pharmacology : Advances and Applications
|
February 28, 2020
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
Haiyan Li, Zhenhua Yang, Shuang Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 17, 2012
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir
Ellen G J Hulskotte, Hwa-Ping Feng, Fengjuan Xuan, et al.
Clinical Therapeutics
|
May 5, 2018
A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants
Tommy Tsang Cheung, Joanne Wing Yan Chiu, Man Fung Yuen, et al.
Clinical Therapeutics
|
August 30, 2018
Corrigendum to "A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants" [Clinical Therapeutics 40 (2018) 719-732]
Tommy Tsang Cheung, Joanne Wing Yan Chiu, Man Fung Yuen, et al.
Page
of 4